MabVax Therapeutics Holdings, Inc. announced the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for products under development. Dr. Resnick joined the company in March 2016. He is an experienced biopharmaceutical executive with over 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration. From January 2013 to March 2016, Dr. Resnick was Senior Vice President, for Juventas Therapeutics where he was responsible for business and commercial strategy and working with executive management overseeing clinical development and financial and business strategies. From January
2008 to January 2012 he was Vice President, Business Development and member of the executive management team for Intellikine, Inc., responsible for managing alliances and leading the business development strategy that resulted in securing an acquisition by Takeda Pharmaceuticals.